BioSpace News Archive

Business

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its fourth quarter and full year 2023 financial results before market open on Thursday, March 21, 2024.

March 14, 2024
·
2 min read
Lone Star Bio

TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024

TFF Pharmaceuticals, Inc. announced that Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals will be presenting a corporate overview at the 36th Annual Roth Conference being held March 17-19, 2024 in Dana Point, California.

March 14, 2024
·
4 min read
Business

I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab (the “Company”) (NASDAQ: IMAB) today announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.

March 14, 2024
·
19 min read
Policy

FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population

Global Liver Institute recognizes the importance of the first approval by the U.S. Food and Drug Administration of a medication for nonalcoholic steatosis.

March 14, 2024
·
4 min read
Biotech Bay

Evie Ring’s Pulse Oximeter Exceeds FDA Accuracy Guidelines in Movano Health’s Second Hypoxia Trial

Movano Health (Nasdaq: MOVE) has completed another hypoxia trial with the University of California, San Francisco (UCSF) yielding new blood oxygen saturation (SpO2) data, confirming the accuracy of its Evie Ring pulse oximeter exceeds the U.S. Food and Drug Administration (FDA) guidelines.

March 14, 2024
·
4 min read
Biotheus Expanded Their Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific Antibody-Drug Conjugates

Biotheus Inc. and Hansoh Pharmaceutical Group Co., Ltd., China’s leading innovation-driven pharmaceutical company, jointly announced that the two parties will further expand their strategic collaboration, following their current partnership since 2022.

March 14, 2024
·
3 min read
FDA

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi®.

March 14, 2024
·
23 min read
Business

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

March 14, 2024
·
5 min read
Genetown

Allonnia Launches Mining Advisory Board to Support Development and Integration of Biological Solutions for the Mining Industry

Allonnia, the bio-ingenuity company dedicated to extracting value where others see waste, announced the establishment of their Mining Advisory Board.

March 14, 2024
·
4 min read
Drug Development

858 Therapeutics to Present Preclinical Data on ETX-19477 at the AACR 2024 Annual Meeting

858 Therapeutics today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

March 14, 2024
·
2 min read